Trial Profile
A phase II study of 10-propargyl-10-deazaaminopterin (PDX) in patients with advanced non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2010
Price :
$35
*
At a glance
- Drugs Pralatrexate (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2005 New trial record.